Intranasal Drug Delivery Devices Market Size, Share, and Trends 2024 to 2034

The global intranasal drug delivery devices market size was USD 1.52 billion in 2023, calculated at USD 1.70 billion in 2024 and is expected to reach around USD 4.41 billion by 2034, expanding at a CAGR of 10% from 2024 to 2034.

  • Last Updated : August 2024
  • Report Code : 1253
  • Category : Healthcare

Intranasal Drug Delivery Devices Market Size and Forecast 2024 to 2034

The global intranasal drug delivery devices market size accounted for USD 1.70 billion in 2024 and is expected to reach around USD 4.41 billion by 2034, expanding at a CAGR of 10% from 2024 to 2034. The North America intranasal drug delivery devices market size reached USD 590 million in 2023.

Intranasal Drug Delivery Devices Market Size 2024 to 2034

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Intranasal Drug Delivery Devices Market Key Takeaways

  • North America led the global market with the highest market share of 39% in 2023.
  • By systems, the multi-dose systems segment has held the largest market share in 2023.
  • By application, the asthma segment captured the biggest revenue share in 2023.
  • By end user, the hospitals segment registered the maximum market share in 2023.

U.S. Intranasal Drug Delivery Devices Market Size and Growth 2024 to 2034

The U.S. intranasal drug delivery devices market size was estimated at USD 410 million in 2023 and is predicted to be worth around USD 1,230 million by 2034, at a CAGR of 10.1% from 2024 to 2034.

U.S. Intranasal Drug Delivery Devices Market Size 2024 to 2034

The research report covers key trends and prospects of intranasal drug delivery devices products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, intranasal drug delivery devicesmarket is conquered by North America owing to high incidence of asthma and presence of sophisticated healthcare framework. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing healthcare expenditure and growing investment by major manufactures to launch new products.

Intranasal Drug Delivery Devices Market Share, By Region, 2023 (%)

Intranasal Drug Delivery Devices Market Growth Factors

  • Increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy
  • High prevalence of cardiovascular diseases
  • Patent expiration of popular drugs, increased cases of cancer and diabetes
  • Growing Adoption of Self-Administration Practices
  • Technological advancements

Market Scope

Report Highlights Details
Market Size in 2023 USD 1.52 Billion
Market Size in 2024 USD 1.70 Billion
Market Size by 2034 USD 4.41 Billion
Growth Rate from 2024 to 2034 CAGR of 10%
Base Year 2023
Forecast Period 2024 to 2034
Segment Covered System, Container, Application, End User, and Regions
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East and Africa

 

Major Trends in the Intranasal Drug Delivery Devices Industry:

Considering the wide-ranging awareness in nasal drug delivery and the possible advantages of intranasal administration, it is anticipated that novel nasal drug delivery products will continue to arrive at the market and advance exponentially in the forthcoming years. The prospects in the worldwide market for the intranasal drug delivery devices have drawn huge expenditure by major companies in research and development activities. Moreover, in the emerging countries such as India, China, etc. having low labor and clinical trials costs, will further aidin drawing market players to these nations and will observe an exponential development in the forthcoming years. The novel nasal drug delivery devices are expected to reach the market and grow significantly in the upcoming years due to the prevalent awareness regarding nasal drug delivery and the probable advantages of intranasal administration. The prospects in the global market for the intranasal drug delivery devices have invited huge investments by key companies in the research and development activities. Furthermore, in the emerging economies in the Asia Pacific region, which have lower costs of clinical trials and labor, will further help to draw market players to this region and will observe an exponential development in the near future. Through the development of spontaneous patient-friendly modernizations, intranasal medication delivery devices and apparatuses enable treatments to remain on the cutting edge along with making life better for affected individuals, thereby offering a great prospect for its overall business to flourish in the forthcoming years. To take completebenefit of these openings offered by nasal delivery of medications, innovative methods to overcome the biological blockades to delivery are being established. The technological advancements in many of the nasal drug transfer devices currently, consists of the powder preparation and carrier technology, intended for increased medication absorption through its muco-adhesive features and a transfer device technology intended for simple use, and comprehensive and consistent transfer of intranasal powder preparations. This technology can be employed to a wide range of medications, including peptides, small molecules, and biologics.

System Insights

Multi-dose Systems Segment Reported Foremost Market Stake in 2023

Multi-dose systems segment recorded the prime market share in the global intranasal drug delivery devices market in 2023. The ability of multi-dose systems to deliver drugs by avoiding formulation contamination is the major reason for high market share of multi-dose systems. The factors such as better tolerance and efficient use are expected to increase the usage of the multi-dose intra-nasal drug delivery systems over the estimate period.

The metered dose systems are projected grow at the highest CAGR during the forecast period mainly due to new product launches.

Application Insights

Asthma is Projected to Dominate the Application Segment of Intranasal Drug Delivery Devices Market Revenue

Intranasal drug delivery devices are rapidly being employed for the management of asthma. As per the Centers for Disease Control and Prevention (CDC), 1 in 13 persons have asthma.Thus, high incidence of asthma and ongoing research and development activity in intranasal drug delivery devices for better absorption is the major reason for the high revenue share of asthma.

Rhinitissegment will expand at a significant CAGR during the forecast time-frame.

End User Insights

Hospitals Projected to Dominate the End-User Segment of Intranasal Drug Delivery Devices Market Revenue

Hospitals have a high flow of patients with respiratory disorders when compared to small clinics. Furthermore, hospitals have capital availability to procure latest equipment’s. These factors contribute to the growth of hospital segment.

Intranasal Drug Delivery Devices Market Companies

  • Johnson & Johnson, Inc.
  • Aptar Pharma Group
  • GlaxoSmithKline Plc
  • Aegis Therapeutics LLC
  • H&T Presspart Manufacturing Ltd.
  • AstraZeneca Plc
  • Becton, Dickinson and Company
  • Novartis AG
  • Teleflex Incorporated
  • Vectura Group Plc.

Recent Developments

  • In 2019, AptarGroup, Inc. acquired Noble International, a frontrunner in drug delivery training equipment’s (prefilled syringes, autoinjectors, respiratory and on-body devices) and patient onboarding plans.
  • In 2018, Neurelis, Inc. finished the acquisition of Aegis Therapeutics. The product portfolio of Aegis Therapeutics includes Hydrogel, ProTek, and Intravail non-invasive drug transfer and stabilization advances applicable to a wide-array of molecules encompassingpeptides, therapeutic proteins, non-peptide small molecules and macromolecules. 

Major Market Segments Covered:

By System

  • Metered Dose
  • Multi-Dose Systems
  • Unit-Dose Systems

By Container

  • Non-Pressurized Containers
  • Pressurized Containers

By Application

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion
  • Asthma
  • Others

By End User

  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Frequently Asked Questions

The global intranasal drug delivery devices market was valued at USD 1.52 billion in 2023 and is predicted to reach USD 4.41 billion by 2034.

The global intranasal drug delivery devices market is growing at a CAGR of 10% during the forecast period 2024 to 2034.

Factors such as growing patient preference for nasal drug delivery and increasing popularity of self-administration of medicationsare driving the growth of intranasal drug delivery devices market.High incidence of cardiovascular disorders, increased cancer and diabetes cases, amplified focus on elderly and pediatric patients, and growing demand for home-based healthcare devices are further propelling the intranasal drug delivery devices market expansion across the globe. Additional aspects that are anticipated to fuel this industryare rapid R&D activity and reception of new drug delivery approaches and equipment’s, reformulation of injections and oral medications into the preparations to be administered by the nasal route, and quick onset of action. The simple administration and improved e

North America dominated the global market with a market share of more than 37%.

Asia Pacific is anticipated to grow at the maximum CAGR of around 14% in the forecast period due to high incidence of cancer.

The major companies operating in the worldwide intranasal drug delivery devices market are Johnson & Johnson, Inc., Aptar Pharma Group, GlaxoSmithKline Plc, Aegis Therapeutics LLC, H&T Presspart Manufacturing Ltd., AstraZeneca Plc, Becton, Dickinson and Company, Novartis AG, Teleflex Incorporated, and Vectura Group Plc. among others.

Hospitals accounted for the largest revenue in the end-user segment. High frequency of intranasal drug delivery in hospitals is the key reason for high market share of hospitals.

Intranasal Drug Delivery Devices Market

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Intranasal Drug Delivery Devices Market 

5.1. COVID-19 Landscape: Intranasal Drug Delivery Devices Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Intranasal Drug Delivery Devices Market, By System

8.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by System, 2024-2034

8.1.1. Metered Dose

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Multi-Dose Systems

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Unit-Dose Systems

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global Intranasal Drug Delivery Devices Market, By Container

9.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by Container, 2024-2034

9.1.1. Non-Pressurized Containers

9.1.1.1. Market Revenue and Volume Forecast (Metered Dose)

9.1.2. Pressurized Containers

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global Intranasal Drug Delivery Devices Market, By Application 

10.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by Application, 2024-2034

10.1.1. Chronic Obstructive Pulmonary Disease (COPD)

10.1.1.1. Market Revenue and Volume Forecast (2021-2034)

10.1.2. Rhinitis

10.1.2.1. Market Revenue and Volume Forecast (2021-2034)

10.1.3. Cystic Fibrosis

10.1.3.1. Market Revenue and Volume Forecast (2021-2034)

10.1.4. Nasal Congestion

10.1.4.1. Market Revenue and Volume Forecast (2021-2034)

10.1.5. Asthma

10.1.5.1. Market Revenue and Volume Forecast (2021-2034)

10.1.6. Others

10.1.6.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 11. Global Intranasal Drug Delivery Devices Market, By End User 

11.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by End User, 2024-2034

11.1.1. Ambulatory Surgical Centers

11.1.1.1. Market Revenue and Volume Forecast (2021-2034)

11.1.2. Clinics

11.1.2.1. Market Revenue and Volume Forecast (2021-2034)

11.1.3. Hospitals

11.1.3.1. Market Revenue and Volume Forecast (2021-2034)

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 12. Global Intranasal Drug Delivery Devices Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.1.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.1.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.1.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.1.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.1.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.1.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.1.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.1.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.1.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.2.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.2.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.2.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.2.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.2.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.2.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.2.7.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.2.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.7.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.2.8.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.2.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.2.8.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.3.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.3.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.3.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.3.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.3.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.3.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.3.7.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.3.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.7.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.3.8.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.3.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.3.8.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.4.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.4.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.4.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.4.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.4.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.4.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.4.7.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.4.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.7.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.4.8.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.4.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.4.8.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.5.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.5.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.5.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by System (2021-2034)

12.5.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)

12.5.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)

12.5.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)

Chapter 13. Company Profiles

13.1. Johnson & Johnson, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Aptar Pharma Group

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. GlaxoSmithKline Plc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Aegis Therapeutics LLC

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. H&T Presspart Manufacturing Ltd.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. AstraZeneca Plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Becton, Dickinson and Company

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Novartis AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Teleflex Incorporated

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Vectura Group Plc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

 

15.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us